Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTAN: Apalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204Phase 3Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 25
01
Overview
A Phase 3 trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Aragon Pharmaceuticals. Started Oct 2013; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01946204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946204.